IDH1 and central nervous system cancer: For IDH1‐WT glioma, the strategy focuses on achieving the maximum safe resection due to their poor response to chemotherapy and radiotherapy.[5] Conversely, for IDH1‐MUT gliomas, the priority shifts toward preserving the functional brain tissues, reflecting their sensitivity to chemotherapy and radiotherapy.[6] Therefore, intraoperative IDH1 genotyping of glioma enables physicians to promptly optimize surgical strategies and optimizing postoperative treatments.